Last updated: July 31, 2026
Flagyl I.V. is intravenous metronidazole, an established nitroimidazole antibiotic used against anaerobic bacterial infections and selected protozoal infections. Its commercial position is mature and genericized. Clinical development is focused on metronidazole as an active ingredient, not on new Flagyl I.V. exclusivity. Demand is supported by hospital use in intra-abdominal, gynecologic, colorectal, aspiration-related and severe anaerobic infections, but pricing is constrained by multiple generic suppliers and alternative intravenous antibiotics.
What is Flagyl I.V. and what is it approved to treat?
Flagyl I.V. contains metronidazole, commonly supplied as a 500 mg/100 mL intravenous infusion. The product is administered when oral therapy is not feasible or when rapid systemic treatment is required.
FDA labeling identifies intravenous metronidazole use for serious infections caused by susceptible anaerobic bacteria, including infections involving the:
- Peritoneal cavity
- Female reproductive tract
- Lower respiratory tract
- Skin and skin structures
- Bone and joints
- Central nervous system
- Bloodstream
Metronidazole is also used in combination regimens for mixed aerobic-anaerobic infections and in selected perioperative prophylaxis settings. The drug is not active against aerobic bacteria and is not a substitute for broad-spectrum coverage when aerobic pathogens are suspected.
The FDA label includes warnings concerning carcinogenicity findings in animals, neurologic toxicity, peripheral neuropathy, encephalopathy, seizures, drug interactions with warfarin and lithium, and disulfiram-like reactions with alcohol-containing products. The product label also warns against alcohol or propylene glycol exposure during therapy and for the specified post-treatment period.[1]
What is the current clinical-trial status of Flagyl I.V.?
There is no major late-stage clinical program developing branded Flagyl I.V. as a new product. Metronidazole has a long-established efficacy and safety record, so modern studies generally evaluate it as:
- A comparator or component of a combination regimen.
- A perioperative prophylaxis option.
- A treatment for anaerobic infection in a specific hospital population.
- A component of treatment for Clostridioides difficile infection or protozoal disease.
- A comparator against newer antibiotics or antimicrobial strategies.
ClinicalTrials.gov contains studies involving metronidazole, but many are investigator-initiated, observational, or focused on disease management rather than registration of a new Flagyl I.V. formulation.[2]
Current research themes involving intravenous metronidazole
| Research area |
Role of metronidazole |
Commercial relevance |
| Intra-abdominal infection |
Backbone of combination therapy in some protocols |
Supports hospital demand but does not create exclusivity |
| Surgical prophylaxis |
Alternative or combination prophylaxis agent |
Sensitive to institutional protocols |
| C. difficile infection |
Historically important; increasingly displaced by oral vancomycin and fidaxomicin |
Declining relevance in severe or recurrent disease |
| Anaerobic bacteremia |
Component of directed therapy |
Dependent on local susceptibility and source control |
| Pediatric infection |
Dosing and safety studies |
Supports continued use in hospitals |
| Antimicrobial stewardship |
Comparison with narrower or broader agents |
Can reduce use where alternatives are preferred |
| Drug delivery |
Extended or optimized infusion studies |
Limited ability to support branded pricing |
The clinical-development risk is low because metronidazole is well characterized. The commercial-development opportunity is also limited because a new intravenous metronidazole formulation would compete with inexpensive generic products unless it offered a material advantage in stability, administration time, premixed handling, dosing, or supply reliability.
What is the FDA regulatory status of Flagyl I.V.?
Flagyl I.V. is a legacy FDA-approved metronidazole product. The regulatory market now includes branded legacy products, authorized generic or generic metronidazole injection products, and hospital-distributed presentations.
The relevant regulatory distinction is between the original Flagyl brand and current metronidazole injection products. Hospitals often purchase the active ingredient under generic names rather than under the Flagyl brand. Product availability can differ by:
- Strength
- Container size
- Premixed versus pharmacy-compounded presentation
- Ready-to-use status
- Preservative profile
- Manufacturer
- National Drug Code
- Temporary shortage conditions
FDA’s Drugs@FDA and National Drug Code Directory provide the controlling product and labeling records. FDA’s Drug Shortages database should be used to assess current availability because injectable antibiotics can experience supply interruptions even when the underlying drug has no patent barrier.[3][4]
What patents protect Flagyl I.V. and when does metronidazole lose exclusivity?
Metronidazole is an old small-molecule drug whose original composition-of-matter and core therapeutic patents expired decades ago. Flagyl I.V. does not have a commercially meaningful period of new-molecule exclusivity.
| Exclusivity category |
Current position |
| Original compound patent |
Expired |
| Original formulation protection |
Expired or commercially irrelevant |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable to the general Flagyl I.V. product |
| Data exclusivity for the original product |
Expired |
| Active Orange Book exclusivity protecting the brand |
Not the principal market barrier |
| Generic substitution risk |
High |
The remaining intellectual-property issues, if any, are more likely to concern manufacturing processes, container systems, premixed delivery formats, labeling, or specific formulations. Those rights would not restore broad exclusivity over metronidazole itself.
Is Flagyl I.V. listed in the Orange Book, and are there Paragraph IV challenges?
The Orange Book is relevant to approved metronidazole drug products and any listed patents associated with those products. It is not a reliable measure of commercial protection for a decades-old antibiotic when generic metronidazole injections are already marketed.
Paragraph IV litigation is not the central competitive issue for standard metronidazole injection. A generic applicant could challenge an Orange Book-listed patent by certifying that the patent is invalid, unenforceable, or not infringed. For legacy metronidazole injection products, however, market entry has already occurred across the active ingredient category. The practical risks are therefore:
- Manufacturing interruption
- FDA inspection or compliance action
- Injectable-product recalls
- Container or closure issues
- Sterility failures
- Hospital contracting
- Distributor concentration
- Temporary shortages
These risks are more material than a conventional patent cliff.
What formulations are protected by Flagyl I.V.?
The principal formulation is an intravenous metronidazole solution. Commercial differentiation may involve the following attributes:
- 500 mg/100 mL presentation
- Ready-to-use infusion bag
- Flexible container
- Plastic bottle
- Pharmacy bulk package
- Concentrated solution requiring dilution
- Preservative-free formulation
- Different storage conditions
- Different overwrap or packaging configurations
Any current protection would need to be assessed at the specific product and jurisdiction level. The general metronidazole solution is not protected by a meaningful, enforceable monopoly. Formulation and packaging patents, where present, would typically have narrower scope and could be designed around by generic manufacturers.
How strong is the Flagyl I.V. patent estate?
The patent estate is weak from a product-exclusivity perspective. Its strength can be summarized as follows:
| Factor |
Assessment |
| Core molecule |
No effective exclusivity |
| Intravenous dosage form |
Generic competition established |
| Manufacturing know-how |
Potential operational value, limited legal exclusivity |
| Packaging and delivery |
Possible narrow rights |
| Method of use |
Limited value because broad clinical uses are longstanding |
| Regulatory switching barrier |
Low to moderate |
| Supply-chain barrier |
Moderate |
| Litigation leverage |
Low |
| Brand recognition |
Historically strong, but weaker than generic purchasing economics |
A hospital purchaser is unlikely to pay a substantial premium solely for the Flagyl name when an FDA-approved metronidazole injection is available from multiple suppliers.
What is the competitive landscape for intravenous metronidazole?
The competitive market includes generic injectable metronidazole manufacturers, hospital distributors, group purchasing organizations and alternative antibiotics.
Direct competitors
Direct competitors are generic metronidazole injection products sold by manufacturers such as Baxter, B. Braun, Fresenius Kabi, Hikma, Pfizer or other approved suppliers, depending on the country and presentation. Manufacturer participation changes over time because injectable products are subject to capacity decisions, shortages and contract changes.
Therapeutic alternatives
Depending on infection site and resistance profile, clinicians may consider:
- Piperacillin/tazobactam
- Ampicillin/sulbactam
- Ceftriaxone or cefotaxime combined with metronidazole
- Ertapenem
- Meropenem
- Imipenem/cilastatin
- Clindamycin in selected situations
- Oral or intravenous vancomycin for specific C. difficile settings
Metronidazole maintains a cost advantage in many settings, but it can lose share where hospitals prefer one-agent broad-spectrum therapy, where neurologic toxicity is a concern, or where clinical guidelines favor other treatments.
What is the market outlook for Flagyl I.V.?
Flagyl I.V. revenue should be analyzed as a mature hospital injectable market rather than as a branded growth product. Public financial disclosures generally do not isolate Flagyl I.V. revenue from broader metronidazole or hospital-product portfolios. A standalone, audited global market size for Flagyl I.V. is therefore not a dependable valuation metric.
Five-year base-case projection
| Metric |
2024-2025 baseline |
2026-2028 outlook |
2029-2030 outlook |
| Unit demand |
Stable to slightly declining |
Low-single-digit decline |
Low-single-digit decline |
| Net price |
Flat to declining |
Continued generic pressure |
Low growth only during shortages |
| Branded Flagyl share |
Low |
Low or declining |
Limited residual share |
| Generic share |
Dominant |
Dominant |
Dominant |
| Hospital use |
Stable in core anaerobic indications |
Selective substitution |
Stable niche demand |
| Revenue growth |
Flat to negative |
Negative in normal supply conditions |
Mostly volume and shortage driven |
| Margin profile |
Low to moderate |
Compressed |
Dependent on manufacturing efficiency |
The base case assumes no major shortage and no material change in treatment guidelines. A shortage scenario could produce temporary price increases and higher revenue for suppliers with available inventory. That upside would be episodic, not a durable expansion of market value.
Key demand drivers
- Hospital admissions involving intra-abdominal and pelvic infection
- Surgical procedures requiring anaerobic coverage
- Use in resource-constrained hospitals
- Low acquisition cost
- Familiarity with dosing and safety
- Availability of generic ready-to-use presentations
Key demand pressures
- Antimicrobial stewardship
- Substitution with broad-spectrum single agents
- Reduced use for C. difficile infection
- Preference for oral therapy when clinically appropriate
- Peripheral neuropathy and central nervous system toxicity concerns
- Generic tender pricing
- Hospital formulary consolidation
What generic launch risks exist for Flagyl I.V.?
The conventional generic-launch risk is already realized. Generic metronidazole injection products are established, so a new entrant would face commercial execution risks rather than patent-based entry risk.
A new manufacturer would need to manage:
- ANDA approval and product-specific bioequivalence requirements
- Sterility and aseptic manufacturing controls
- Container-closure integrity
- Stability data
- FDA inspection risk
- Hospital contract access
- Group purchasing organization discounts
- Distributor inventory requirements
- Shortage reporting and continuity planning
The most attractive entry opportunity is a reliable ready-to-use product with dependable supply. Price alone may be insufficient because the market already has low-cost alternatives.
What patent litigation and settlement agreements affect Flagyl I.V.?
There is no major current patent-litigation narrative that materially restricts generic metronidazole injection access. The historic litigation significance of metronidazole relates more broadly to legacy generic drug approvals and pharmaceutical patent practice than to an active Flagyl I.V. patent dispute.
Settlement agreements are unlikely to create a meaningful delayed-entry date for standard intravenous metronidazole because the product category is already genericized. Any relevant dispute should be assessed through FDA Orange Book records, ANDA litigation filings and federal court dockets for the specific formulation and manufacturer.
How does Flagyl I.V. compare with newer anaerobic-treatment options?
| Attribute |
Flagyl I.V. |
Newer or broader alternatives |
| Cost |
Usually low |
Often higher |
| Anaerobic coverage |
Strong |
Often strong |
| Aerobic coverage |
Limited |
Often broader |
| Dosing familiarity |
Very high |
High for established alternatives |
| Patent protection |
None of commercial significance |
Varies by product |
| Supply risk |
Generic injectable risk |
Varies by supplier |
| Neurologic toxicity concern |
Established warning |
Depends on agent |
| Stewardship position |
Narrow utility in selected infections |
May be preferred for polymicrobial disease |
Flagyl I.V. remains commercially relevant where targeted anaerobic coverage is appropriate and cost matters. It is less competitive when clinicians require broad empiric coverage or when treatment guidelines favor newer agents.
Key Takeaways
- Flagyl I.V. is intravenous metronidazole, an established genericized antibiotic.
- No meaningful new-drug exclusivity remains for the original product.
- Clinical trials generally study metronidazole in disease-specific or comparative settings, not as a new branded Flagyl I.V. program.
- Paragraph IV litigation is not the principal market risk.
- Generic competition dominates pricing and hospital procurement.
- The largest commercial risks are injectable manufacturing failures, shortages, recalls and contract loss.
- Base-case demand is stable to modestly declining over the next five years.
- Revenue upside is most likely during temporary shortages, not through durable branded growth.
- Formulation, packaging and ready-to-use delivery may offer limited differentiation, but they do not recreate molecule-level exclusivity.
- Alternative broad-spectrum antibiotics remain the main competitive pressure.
FAQs about Flagyl I.V.
Is Flagyl I.V. still available?
Intravenous metronidazole remains available through generic and branded or legacy product channels, but specific presentations and manufacturers can change. Current availability should be checked against FDA product and shortage records.
Is Flagyl I.V. the same as generic metronidazole injection?
Yes. Flagyl I.V. contains metronidazole. Generic metronidazole injection products generally compete with the same active ingredient, dosage form and route of administration, subject to product-specific labeling.
Does Flagyl I.V. have biosimilar competition?
No. Metronidazole is a small-molecule drug, not a biologic. The relevant competitors are generic drug products, not biosimilars.
Can a generic manufacturer launch Flagyl I.V. without a patent risk?
For standard metronidazole injection, molecule-level patent risk is minimal because the core rights expired long ago. A manufacturer must still address product-specific patents, FDA approval requirements, manufacturing controls and any litigation involving a particular formulation or reference product.
Is intravenous metronidazole still used for C. difficile infection?
Use has declined, particularly for severe, recurrent or preferred-treatment settings. Oral vancomycin and fidaxomicin are commonly favored in current treatment frameworks, while intravenous metronidazole is not an equivalent substitute for delivering drug into the intestinal lumen.[5]
References
- U.S. Food and Drug Administration. (2023). Flagyl I.V. metronidazole injection prescribing information. FDA. https://www.accessdata.fda.gov
- National Library of Medicine. (2024). ClinicalTrials.gov. https://clinicaltrials.gov
- U.S. Food and Drug Administration. (2024). Drugs@FDA. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (2024). FDA Drug Shortages. FDA. https://www.accessdata.fda.gov/scripts/drugshortages/
- Johnson, S., Lavergne, V., Skinner, A. M., et al. (2021). Clinical practice guideline by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America: 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clinical Infectious Diseases, 73(5), e1029-e1044. https://doi.org/10.1093/cid/ciab549
